[ESC 2012]新吞咽功能评估法减少脑卒中患者肺炎发病率

2012-06-17 陈蓉 国际循环网

2012年第21届欧洲卒中会议上,一项最新研究结果显示,检查脑卒中患者是否存在吞咽困难可使其肺炎发病率下降75%,且此项检查简便易行,敏感性与特异性均高。    过去常用的Mann吞咽能力评估(MASA) 约需1小时,而改进式Mann吞咽能力评估(Modified Mann Assessment of Swallowing Ability,MMASA)仅需5分钟,可作为入院常规筛查在床旁进行。如果

2012年第21届欧洲卒中会议上,一项最新研究结果显示,检查脑卒中患者是否存在吞咽困难可使其肺炎发病率下降75%,且此项检查简便易行,敏感性与特异性均高。
  
过去常用的Mann吞咽能力评估(MASA) 约需1小时,而改进式Mann吞咽能力评估(Modified Mann Assessment of Swallowing Ability,MMASA)仅需5分钟,可作为入院常规筛查在床旁进行。如果患者不存在吞咽困难,则可以进食。MMASA从10个方面对吞咽能力进行评估,每项的满分均为10分,总分为100分,以97分作为切点,敏感性为72.3%,特异性为79.2%,阳性预测价值为75.6%,阴性预测价值为81.8%。
  
这项研究在英国Frenchay医院进行,于2009年11月到2011年1月间共纳入100例急性脑卒中患者,平均年龄为78.3岁,男女各半。平均检查时间为发病后55小时,入院后38小时。采用MMASA进行筛查,发现47%的患者存在吞咽困难。Baldwin医生介绍说,在Frenchay医院的脑卒中病房中,每年有12%的患者发生肺炎;而在整个英国,这个数字是16%。采用了这套筛查系统之后,Frenchay医院急性脑卒中患者肺炎的发病率降至3%。据估计,40%-65%的急性脑卒中患者存在吞咽困难。英国指南推荐入院后4小时内对吞咽困难进行筛查,但既有的MASA检查耗时长,难以短期得到评估结果;而新方法简单易行,可以作为常规入院筛查使用。 .

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2010933, encodeId=0743201093338, content=<a href='/topic/show?id=b6ca391652d' target=_blank style='color:#2F92EE;'>#吞咽功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39165, encryptionId=b6ca391652d, topicName=吞咽功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue May 28 07:17:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679047, encodeId=10fe16e9047a8, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Mar 15 01:17:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823148, encodeId=255018231488e, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Jan 06 18:17:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719988, encodeId=3cdf1e199885e, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri May 10 12:17:00 CST 2013, time=2013-05-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2010933, encodeId=0743201093338, content=<a href='/topic/show?id=b6ca391652d' target=_blank style='color:#2F92EE;'>#吞咽功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39165, encryptionId=b6ca391652d, topicName=吞咽功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue May 28 07:17:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679047, encodeId=10fe16e9047a8, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Mar 15 01:17:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823148, encodeId=255018231488e, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Jan 06 18:17:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719988, encodeId=3cdf1e199885e, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri May 10 12:17:00 CST 2013, time=2013-05-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2010933, encodeId=0743201093338, content=<a href='/topic/show?id=b6ca391652d' target=_blank style='color:#2F92EE;'>#吞咽功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39165, encryptionId=b6ca391652d, topicName=吞咽功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue May 28 07:17:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679047, encodeId=10fe16e9047a8, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Mar 15 01:17:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823148, encodeId=255018231488e, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Jan 06 18:17:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719988, encodeId=3cdf1e199885e, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri May 10 12:17:00 CST 2013, time=2013-05-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2010933, encodeId=0743201093338, content=<a href='/topic/show?id=b6ca391652d' target=_blank style='color:#2F92EE;'>#吞咽功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39165, encryptionId=b6ca391652d, topicName=吞咽功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue May 28 07:17:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679047, encodeId=10fe16e9047a8, content=<a href='/topic/show?id=7a2684e600b' target=_blank style='color:#2F92EE;'>#脑卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84760, encryptionId=7a2684e600b, topicName=脑卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091e27733095, createdName=weihongyv, createdTime=Fri Mar 15 01:17:00 CST 2013, time=2013-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823148, encodeId=255018231488e, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Jan 06 18:17:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719988, encodeId=3cdf1e199885e, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Fri May 10 12:17:00 CST 2013, time=2013-05-10, status=1, ipAttribution=)]

相关资讯

Lancet:IST-3卒中试验结果公布

       2012年欧洲卒中大会于5月22~25日在葡萄牙首都里斯本召开。本次大会公布了第3次国际卒中试验(IST-3)的主要结果,及静脉血栓溶解的主要结果及相关最新荟萃分析结果。相关研究结果于近日在线发表于《柳叶刀》(The Lancet)杂志。IST-3主要结果IST-3试验结果表明,对其所收录的各类患者,尽管急性缺血性卒中发病后

[ESC 2012]CD34+造血干细胞可安全用于缺血性卒中患者

       对急性重度缺血性卒中(IS)患者动脉内给予自体经免疫选择CD34+造血干细胞治疗是安全的,这是英国学者S. Banerjee等人在2012欧洲卒中大会(ESC 2012)上公布的其研究结果。该研究于近期发表于《脑血管病》杂志【Cerebrovasc Dis 2012; 33 (suppl 2)1-944】   既往研究显示:非人类模型的造

[ESC 2012]腔隙性卒中强化降压是否可行?

       在最近召开的2012欧洲脑卒中大会(ESC)上,加拿大学者公布的一项研究显示:有明确脑小血管疾病的患者降低收缩压是可行和安全的。   高血压是最常见的、并可改变的卒中危险因素,尤其是对于脑小血管疾病所致卒中。收缩压下降10 mmHg与卒中复发率显著降低相关。但控制收缩压以预防卒中仍做得不好。此分析旨在确定腔隙性卒中患者收缩压下降的预测

ESC年会:头3小时是扼制颅内出血扩大的关键

美国学者近期在2012欧洲卒中大会(ESC 2012)上公布的一项研究显示:颅内出血(ICH)容积扩大的患者在发病后最初3小时血压会升高,但此后没有升高。这些结果表明,需要尽早给予旨在扼制血肿扩大的降血压治疗,以便获得潜在益处。   ICH扩大与血压升高相关,但在此研究之前并不清楚发生与不发生ICH扩大患者之间病程早期的血压升高如何不同。研究人员参加现场使用镁卒中疗法(FAST-MAG)临床试验的

[ESC 2012]醒后卒中:溶栓治疗安全有效

       在近期召开的2012欧洲卒中大会上,奥地利学者公布的一项迄今所发表的最大规模的有关醒后卒中患者溶栓治疗的数据集证明:大量醒后卒中患者可从溶栓治疗中获益,且大出血和死亡发生率并没有增加;溶栓治疗可独立预测早期神经系统的显著改善。   由于当前缺乏醒后卒中患者优化管理和早期转归的数据,迄今绝大多数醒后卒中患者都被排除溶栓治疗。此项研究旨在

[ESC 2012]颈动脉狭窄治疗荟萃分析:EVT还是CEA

       在最近召开的2012欧洲卒中大会(ESC)上,瑞士和英国学者共同开展的有关血管内治疗(EVT)相比于动脉内膜切除术(CEA)治疗颈动脉狭窄疗效的最新Cochrane荟萃分析显示:与CEA相比,EVT患者的围手术期卒中或死亡风险增加,但此增加危险仅见于年龄较大的患者。EVT的心肌梗死、颅神经麻痹和入路部位血肿发生风险较小。两种治疗预防围手术期后卒